These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 17714762

  • 1. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
    Kondo T, Nakazawa T, Murata S, Kurebayashi J, Ezzat S, Asa SL, Katoh R.
    Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
    [Abstract] [Full Text] [Related]

  • 2. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y.
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [Abstract] [Full Text] [Related]

  • 3. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W, Li XH, Zhang YH, Li J, Chen J, Zhao P, Li QY, Xiang JJ, Li X, Xu RJ.
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
    [Abstract] [Full Text] [Related]

  • 4. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
    Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A.
    Br J Cancer; 2007 May 21; 96(10):1549-53. PubMed ID: 17453004
    [Abstract] [Full Text] [Related]

  • 5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 6. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.
    Clin Endocrinol (Oxf); 2008 Apr 01; 68(4):618-34. PubMed ID: 18070147
    [Abstract] [Full Text] [Related]

  • 7. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M.
    Clin Cancer Res; 2007 Feb 15; 13(4):1341-9. PubMed ID: 17317846
    [Abstract] [Full Text] [Related]

  • 8. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A, Kakudo K.
    Pathol Int; 2007 Jan 15; 57(1):12-20. PubMed ID: 17199737
    [Abstract] [Full Text] [Related]

  • 9. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 10. BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.
    Jakubowski M, Hunt JL.
    Am J Surg Pathol; 2009 Nov 15; 33(11):1590-3. PubMed ID: 19738460
    [Abstract] [Full Text] [Related]

  • 11. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
    Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.
    Cancer; 2007 Sep 15; 110(6):1218-26. PubMed ID: 17685465
    [Abstract] [Full Text] [Related]

  • 12. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
    Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP.
    Hum Pathol; 2013 Nov 15; 44(11):2563-70. PubMed ID: 24071017
    [Abstract] [Full Text] [Related]

  • 13. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant.
    Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK.
    Hum Pathol; 2011 Apr 15; 42(4):500-6. PubMed ID: 21167555
    [Abstract] [Full Text] [Related]

  • 14. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P.
    Cancer Res; 2009 Nov 01; 69(21):8317-25. PubMed ID: 19861538
    [Abstract] [Full Text] [Related]

  • 15. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose.
    Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M, Cologne J, Hayashi Y, Nakata Y, Nakachi K, Hamatani K.
    Mol Carcinog; 2007 Mar 01; 46(3):242-8. PubMed ID: 17186541
    [Abstract] [Full Text] [Related]

  • 16. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R.
    Endocr Relat Cancer; 2006 Jun 01; 13(2):455-64. PubMed ID: 16728573
    [Abstract] [Full Text] [Related]

  • 17. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
    Gauchotte G, Philippe C, Lacomme S, Léotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM, Bressenot A.
    Pathology; 2011 Aug 01; 43(5):447-52. PubMed ID: 21716161
    [Abstract] [Full Text] [Related]

  • 18. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
    Nicolussi A, D'Inzeo S, Mincione G, Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, Capalbo C, Di Gioia C, Nardi F, Giannini G, Coppa A.
    Int J Oncol; 2014 Feb 01; 44(2):548-56. PubMed ID: 24316730
    [Abstract] [Full Text] [Related]

  • 19. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D, Keutgen XM, Crowley M, Filicori F, Aldailami H, Hoda R, Liu YF, Hoda RS, Scognamiglio T, Jin M, Fahey TJ, Zarnegar R.
    Ann Surg Oncol; 2012 Mar 01; 19(3):973-80. PubMed ID: 21879273
    [Abstract] [Full Text] [Related]

  • 20. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1623-9. PubMed ID: 16533790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.